Current Report · Items 5.07 · 8-K
Evolus, Inc.
EOLSNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 11, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.…
Filed Jun 12, 2026Accepted Jun 12, 2026, 4:19 PM EDTCIK 1570562Accession 0001570562-26-000076
Company context
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Current securities
Disclosure sections
Items 5.07Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 11, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.
The results for each matter voted on by the stockholders at the Annual Meeting were as follows:
Proposal 1: The stockholders of the Company elected each of Brady Stewart and Vikram Malik as Class II directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II Directors were as follows:
Nominee Term Expiring For Withhold Broker Non-Vote
─────────────────────────────────────────────────────────────────────────────────────────
Brady Stewart 2029 38,479,626 1,662,228 11,183,774
Vikram Malik 2029 21,310,653 18,831,201 11,183,774
Proposal 2: The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:
For Against Abstain
────────────────────────────────────────
51,230,324 63,992 18,696
Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of the stockholders’ vote with respect to the approval, on an advisory basis of the Company's named executive officers were as follows:
For Against Abstain Broker Non-Vote
─────────────────────────────────────────────────────────────
39,350,651 336,958 441,629 11,183,774